In vitro activity of gemifloxacin (SB 265805; LB20304a) against human mycoplasmas

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 3, 2000, Pages 367-369

  Hannan, Peter C T ^a   Woodnutt, Gary ^b  

^a Mycoplasma Experience Ltd   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; GEMIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; GRAM NEGATIVE INFECTION; MYCOPLASMA GENITALIUM; MYCOPLASMA HOMINIS; MYCOPLASMA PNEUMONIAE; NONHUMAN; UREAPLASMA UREALYTICUM;

EID: 0034008105     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.3.367     Document Type: Article

References (10)

1. Boswell, F. J., Andrews, J. M. & Wise, R. (1999). The comparative in-vitro activity of gemifloxacin, a novel fluoroquinolone. (P413). Journal of Antimicrobial Chemotherapy 44, Suppl. A, 132.
2. Smith, J. T. (1984). Awakening the slumbering potential of the 4-quinolone antibacterials. Pharmaceutical Journal 233, 299-305.
3. Hannan, P. C. (1998). Comparative susceptibilities of various AIDS-associated and human urogenital tract mycoplasmas and strains of Mycoplasma pneumoniae to 10 classes of antimicrobial agent in vitro. Journal of Medical Microbiology 47, 1115-22.
4. Hannan, P. C., Windsor, G. D., de Jong, A., Schmeer, N. & Stegemann, M. (1997). Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones. Antimicrobial Agents and Chemotherapy 41, 2037-40.
5. Waites, K. B., Duffy, L. B., Schmid, T., Crabb, D., Pate, M. S. & Cassell, G. H. (1991). In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to sparfloxacin and PD 127391. Antimicrobial Agents and Chemotherapy 35, 1181-5.
6. Hannan, P. C. (1995). Antibiotic susceptibility of Mycoplasma fermentans strains from various sources and the development of resistance to aminoglycosides in vitro. Journal of Medical Microbiology 42, 421-8.
7. Allen, A., Bygate, E., Teillol-Foo, M., Oliver, S. D., Johnson, M. R. & Ward, C. (1999). Multiple-dose pharmacokinetics and tolerability of gemifloxacin following oral doses to healthy volunteers. (P418). Journal of Antimicrobial Chemotherapy 44, Suppl. A, 133.
8. Bébéar, C. M., Renaudin, H., Schaeverbeke, T., Leblanc, F. & Bébéar, C. (1999). In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas. Journal of Antimicrobial Chemotherapy 43, 711-14.
9. Bébéar, C. M., Renaudin, H., Boudjadja, A. & Bébéar, C. (1998). In-vitro activity of BAY 12-8039, a new fluoroquinolone, against mycoplasmas. Antimicrobial Agents and Chemotherapy 42, 703-4.
10. Cohen, M. A. & Huband, M. D. (1997). In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs. Journal of Antimicrobial Chemotherapy 40, 308-9.